Pharma News

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Docetaxel injection, non-alcohol formula for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. Eagle entered into an exclusive licensing agreement with Teikoku Pharma USA Inc. in October 2015 to market, sell and distribute Docetaxel injection in the US.

Blocking a naturally occurring protein responsible for transporting fats like cholesterol around the body may help increase your lifespan, new research has found.

Premature birth, a leading cause of death of newborns worldwide, could be prevented by blocking a molecule in the uterus, suggests a new research.

Bioactive glass can be used in tooth fillings to reduce the ability of bacteria to attack composite tooth fillings, and perhaps even provide some of the minerals needed to replace those lost to tooth decay, engineers from Oregon State University said.

[adsense:336x280:8701650588]

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure. ARX-04 (sufentanil sublingual tablet, 30 mcg) is being developed for the treatment of moderate-to-severe acute pain in adult patients administered by a healthcare professional in a medically supervised setting.

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Famotidine Tablets USP, 20 mg and 40 mg.

Celgene Corporation announced the settlement of litigation with Natco Pharma Ltd. of India, Natco's U.S. partner, Arrow International Limited, and Arrow's parent company, Watson Laboratories, Inc. (a wholly-owned subsidiary of Allergan plc) relating to patents for REVLIMID® (lenalidomide).

New research has revealed how malaria parasites cause an inflammatory reaction that sabotages our body's ability to protect itself against the disease.

Can the emergence of antibiotic-resistant bacteria be squarely blamed on the misuse and overuse of antibiotics? No, there is more to the problem than the misuse of common medications, says a University of Georgia researcher.